S Persiani

Summary

Affiliation: Rotta Research Laboratorium
Country: Italy

Publications

  1. ncbi Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males
    S Persiani
    Rotta Research Laboratorium, Monza, Italy
    Int J Clin Pharmacol Ther 40:198-206. 2002
  2. ncbi Pharmacokinetic profile of dexloxiglumide
    Stefano Persiani
    Departments of Clinical Pharmacology and Drug Metabolism, Pharmacokinetics and Dynamics, Rotta Research Laboratorium Rottapharm, Monza, Italy
    Clin Pharmacokinet 45:1177-88. 2006
  3. ncbi Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients
    S Persiani
    Rotta Research Laboratorium, S p A Via Valosa di Sopra, 7 9, 20052 Monza MI, Italy
    Biopharm Drug Dispos 22:73-81. 2001
  4. ncbi Strategies to assess the drug interaction potential in translational medicine
    Stefano Persiani
    Department of Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm SpA, Via Valosa di Sopra, 7, 20052 Monza, MI, Italy
    Expert Opin Drug Metab Toxicol 2:675-86. 2006
  5. ncbi Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man
    S Persiani
    Clinical Pharmacology Department, Rotta Research Laboratorium Rottapharm, Monza, Italy
    Osteoarthritis Cartilage 13:1041-9. 2005
  6. ncbi Translational medicine 2006
    Stefano Persiani
    Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm SpA, Via Valosa di Sopra, 9, 20052 Monza (MI, Italy
    IDrugs 9:253-5. 2006
  7. ncbi Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
    S Persiani
    Rotta Research Laboratorium Rottapharm, Monza, Italy
    Osteoarthritis Cartilage 15:764-72. 2007
  8. ncbi Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma
    Aldo Roda
    Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, I 40126 Bologna, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 844:119-26. 2006
  9. ncbi Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide
    Abhijeet S Jakate
    Department of Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Harborside Financial Center Plaza V, Jersey City, NJ 07311, USA
    Br J Clin Pharmacol 60:498-507. 2005
  10. ncbi Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women
    Partha Roy
    Department of Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ 07311, USA
    J Clin Pharmacol 45:329-36. 2005

Collaborators

Detail Information

Publications13

  1. ncbi Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males
    S Persiani
    Rotta Research Laboratorium, Monza, Italy
    Int J Clin Pharmacol Ther 40:198-206. 2002
    ..To assess the pharmacokinetics, safety and tolerability of dexloxiglumide, a new CCK1 receptor antagonist currently under development for the treatment of the constipation-predominant irritable bowel syndrome...
  2. ncbi Pharmacokinetic profile of dexloxiglumide
    Stefano Persiani
    Departments of Clinical Pharmacology and Drug Metabolism, Pharmacokinetics and Dynamics, Rotta Research Laboratorium Rottapharm, Monza, Italy
    Clin Pharmacokinet 45:1177-88. 2006
    ..The results of different drug interaction studies have indicated that no clinically relevant metabolic and concomitant drug-drug interactions are expected during the clinical use of dexloxiglumide...
  3. ncbi Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients
    S Persiani
    Rotta Research Laboratorium, S p A Via Valosa di Sopra, 7 9, 20052 Monza MI, Italy
    Biopharm Drug Dispos 22:73-81. 2001
    ..Finally, the safety and tolerabilty of the drug administered to mild asthmatic patients was good up to the maximum investigated dose of 8 mg...
  4. ncbi Strategies to assess the drug interaction potential in translational medicine
    Stefano Persiani
    Department of Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm SpA, Via Valosa di Sopra, 7, 20052 Monza, MI, Italy
    Expert Opin Drug Metab Toxicol 2:675-86. 2006
    ....
  5. ncbi Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man
    S Persiani
    Clinical Pharmacology Department, Rotta Research Laboratorium Rottapharm, Monza, Italy
    Osteoarthritis Cartilage 13:1041-9. 2005
    ..This study investigated the oral pharmacokinetics and dose-proportionality of glucosamine after administration of the patented crystalline glucosamine sulfate in man...
  6. ncbi Translational medicine 2006
    Stefano Persiani
    Drug Metabolism, Pharmacokinetics and Dynamics, Rottapharm SpA, Via Valosa di Sopra, 9, 20052 Monza (MI, Italy
    IDrugs 9:253-5. 2006
  7. ncbi Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
    S Persiani
    Rotta Research Laboratorium Rottapharm, Monza, Italy
    Osteoarthritis Cartilage 15:764-72. 2007
    ..We investigated the synovial and plasma glucosamine concentrations in osteoarthritic patients following oral administration of crystalline glucosamine sulphate at the therapeutic dose of 1500mg once-a-day for 14 days...
  8. ncbi Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma
    Aldo Roda
    Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, I 40126 Bologna, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 844:119-26. 2006
    ....
  9. ncbi Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide
    Abhijeet S Jakate
    Department of Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Harborside Financial Center Plaza V, Jersey City, NJ 07311, USA
    Br J Clin Pharmacol 60:498-507. 2005
    ..05). CONCLUSIONS: Ketoconazole caused a minimal increase while fluconazole caused a moderate increase in dexloxiglumide systemic exposure with no change in the adverse event profile of dexloxiglumide...
  10. ncbi Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women
    Partha Roy
    Department of Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ 07311, USA
    J Clin Pharmacol 45:329-36. 2005
    ....
  11. ncbi Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450
    Michael Hall
    Department of In Vitro Metabolism, Huntingdon Life Sciences Ltd, Huntingdon, UK
    Biopharm Drug Dispos 25:163-76. 2004
    ..i.d. and the unbound fraction (0.03) of DEX in human plasma, no clinically relevant metabolic interactions with other CYP substrates are predicted...
  12. ncbi Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport
    Sanna Tolle-Sander
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, USA
    J Pharm Sci 92:1968-80. 2003
    ..In vitro, dexloxiglumide was moderately modulated by P-gp and MRP1, which provides a rationale for the design of drug interaction studies...
  13. ncbi Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide
    Franca Formelli
    Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy
    Cancer Chemother Pharmacol 62:655-65. 2008
    ..Pharmacokinetic data on fenretinide (4-HPR) are scant, thus limiting the rational use of the drug. We investigated the pharmacokinetics of 4-HPR and its active metabolite 4-oxo-fenretinide (4-oxo-4-HPR)...